R&D tax credits for life sciences.
From medical-device makers to digital-health and biotech teams, UAE life-sciences companies are resolving real scientific uncertainty. Some of that work can qualify for the R&D Tax Credit. The discipline is proving precisely which part.
How qualifying R&D shows up in life sciences.
The UAE regime tests every project against five conditions in Ministerial Decision No. 24 of 2026, Article 3(1), assessed with regard to the OECD Frascati Manual. Here is what each looks like in a device, an assay or a clinical algorithm.
Novel
A device, method or therapy aimed at new scientific knowledge.
Creative
Original hypotheses, not routine application of known technique.
Uncertain
Whether a mechanism, device or method works is genuinely unknown.
Systematic
Planned, documented experiments and validation.
Transferable
Results reproducible and generalisable, not one-off.
The kind of work that qualifies.
Illustrative projects across medical devices, diagnostics and health data. Eligibility is always confirmed project by project.
Medical device development
A medical device whose design or performance cannot be reached with established methods.
Clinical-grade algorithms
A digital-health algorithm validated to clinical performance on new data.
Formulation & bioprocess
Formulation or bioprocess work to make a therapy stable, scalable or deliverable.
Novel assays
Assay or biomarker development where the method itself is uncertain.
Health data integration
Integrating clinical and genomic data in ways existing platforms cannot support reliably.
Design for approval
Engineering a device or process to meet a regulatory bar that demands genuine technical development.
Genuine R&D, not routine engineering.
The value we add is drawing this line correctly claiming what qualifies, and defending it, while leaving out what does not.
- Resolving scientific uncertainty about whether a device, method or therapy works.
- Systematic experimentation, validation and iteration.
- Formulation, bioprocess or assay development with uncertain outcomes.
- Engineering clinical-grade performance beyond current capability.
- Routine clinical administration and standard trial logistics.
- Applying an established, validated method without uncertainty.
- Cosmetic changes to an existing, approved device.
- Market access and reimbursement analysis with no technical uncertainty.
AED 396M+
ICAEW Chartered Accountants, AED 396M+ (£80M+) in R&D incentives secured in the UK 1,300+ R&D claims processed (UK practice) – including medical devices, diagnostics, biotech and digital health. The same chartered method now applies to the UAE.
“Simplified the R&D claim process completely. Their expertise in life sciences made all the difference.”
Ducentis BioTherapeutics life sciences client
We are preparing UAE pre-approval submissions through TAWWER now. UAE outcomes will be published here as claims complete, subject to client consent.
Do clinical trials qualify?
The administration and logistics of a standard trial usually do not. But experimental work to resolve scientific uncertainty – whether a mechanism, device or method actually works – frequently does. We separate the two carefully.
We develop software for healthcare. Which side is it on?
It depends on the uncertainty. Building a clinical-grade algorithm whose performance is genuinely unknown can qualify; standard application development around it does not.
Is regulatory work eligible?
The paperwork itself is not. But engineering a device or process to meet a regulatory performance bar, where achieving it required uncertain technical development, can form part of a qualifying project.
What evidence will we need?
Contemporaneous records: the scientific uncertainty, the experiments and validation done to resolve it, and project-level cost and staff-time allocation. We build this as the work happens – and Council pre-approval through the TAWWER platform is mandatory before claiming. Applications are submitted via TAWWER, accessed with UAE PASS and authorised by the signatory registered with the Federal Tax Authority. As at 27 October 2026, calendar-year 2026 companies must apply within 40 business days of 31 December 2026, which is 26 February 2027. Work already under way can be included if it was recorded as it happened.
Making things here? Let’s find what qualifies.
We assess your projects against the five criteria, prepare and file your TAWWER pre-approval submission with the Council, and build the evidence before a single figure is claimed.